Archives: GVB release

PRINEVILLE, Ore., Jan. 3, 2024 — GVB Biopharma, a pioneer in the hemp and cannabis industry, is thrilled to announce its transition back to a private entity controlled by its founding team as of December 28th, 2023. Acquired by NASDAQ listed 22nd Century Group in May 2022, this strategic move marks a new chapter in GVB’s story.

As a privately-held company, GVB Biopharma is uniquely positioned to leverage its industry-leading expertise in research, genetics, and proprietary technologies. This transition allows for a more agile approach in meeting the evolving needs of the global hemp and cannabis markets, while pursuing ambitious growth and excellence in serving its customers.

GVB Biopharma remains at the forefront of the industry with its cutting-edge cryogenic hemp extraction methods, refining, conversion, and advanced product formulation technologies. As a leading supplier of cannabinoids, GVB is committed to maintaining its reputation for high-quality, trusted products.

“As the hemp industry continues to mature, our vision and capabilities align perfectly with the market’s direction,” said Drew Spiegel, Chief Executive Officer of GVB Biopharma. “We are excited to lead the charge in this next phase of industry growth, driven by our commitment to quality, innovation, and our valued customers.”

About GVB Biopharma
GVB Biopharma is a world leader in the hemp and cannabis sector, specializing in research, genetics, proprietary extraction, refining, and product formulation technologies. The company offers an unparalleled range of high-quality products and services, backed by robust manufacturing capabilities and a deep understanding of regulatory landscapes. As a trusted partner in the global hemp industry, GVB Biopharma is dedicated to advancing wellness and health through its innovative solutions.

Contact:
Sebastian Ravitz
Chief Marketing Officer
(801) 203-0887
press@gvbbiopharma.com
gvbbiopharma.com

LAS VEGAS, March 30, 2022 — GVB Biopharma, a biopharmaceutical company specializing in hemp and cannabis-related white-label consumer products, announced today that its website has launched sales of cannabigerolic acid isolates, popularly known as CBGa.

CBGa is the carboxylic acid form of cannabigerol, known as CBG. It is a precursor molecule to delta-9-tetrahydrocannabinol, one of the primary psychoactive cannabinoids in Cannabis sativa. CBGa is non-intoxicating, and has unique benefits described by scientific literature and by consumers. CBGa is important for cannabinoid research and production.

Recently, CBGa has been the focus of high-profile research studies on COVID-19 transmission and on epilepsy management. In January, a study conducted by Oregon State University was published in the peer-reviewed Journal of Natural Products. The research indicated CBGa has the potential to prevent cellular transmission of the SARS-CoV-2 coronavirus that causes COVID-19. A study published in the British Journal of Pharmacology last August demonstrated that CBGa had potent anti-seizure effects in certain mouse models of epilepsy.

GVB Biopharma’s CBGa isolate product contains 95–99% CBGa.

As the standard bearer for high-integrity manufacturing and processing in the hemp cannabinoid industry, GVB Biopharma is proud to introduce one of its newest products in CBGa. GVB’s unparalleled commitment to generating the highest quality consumer products begins with its state-of-the-art hemp processing facilities in central Oregon. It is further supported by white-label consumer product manufacturing operations in Las Vegas, administrative headquarters in Los Angeles and an expanding palette of national sales offices. GVB’s vast national and global reach allows it to meet the exploding demand for hemp cannabinoids and be an indispensable industry partner for entrepreneurs and brands serving this market’s needs.

SOURCE GVB Biopharma

LAS VEGAS, March 21, 2022 — With validation of its Novel Food application to the FSA, GVB Biopharma continues to strengthen its UK and European activities.

GVB is one of the largest US CBD manufacturers and has several modern production facilities. GVB is one of the few true “seed to shelf” suppliers remaining in this space. GVB has a dedication to continuous improvement in all its production processes and has developed a proprietary extraction process to ensure that its customers receive the finest quality products in the most efficient manner.

GVB’s proprietary extraction process allows GVB to provide for very specific tailored products for an expanding and increasingly diverse marketplace. As one of the most established US manufactures GVB is bringing its experience, knowledge and heritage to the UK and European Markets to help business grow with a trusted partner.

Jack Feldman, Co-founder & President says, “We see the potential and growth opportunity in the UK & Europe growing daily. We are looking to grow our current capabilities across all departments and intend to increase our presence substantially. Very few companies can offer the portfolio of products GVB Biopharma can, from the simplest of requests to more complex needs. The market has been in a state of flux and we welcome the forthcoming regulatory clarity”.

Presence in the UK & Europe will allow GVB to produce products to meet various compliance requirements while keeping inventory localized.

SOURCE GVB Biopharma

GRASS VALLEY, Ore., Feb. 1, 2022 — GVB Biopharma, a biopharmaceutical company specializing in hemp and cannabis-related consumer products, announced today that it is experiencing a sizable increase in interest and orders for cannabidiolic acid, a cannabinoid popularly known as CBDa.

Since the first month that CBDa sales began at GVB, internal data shows that the company has seen a 5,000% increase in CBDa orders. Revenue from CBDa sales has increased by a staggering 16,900%.

CBDa, a non-intoxicating compound, recently garnered significant attention when Oregon State University researchers released the results of a study indicating CBDa binds to the SARS-CoV-2 spike protein. CBDa originates primarily from the seedless flowers of cannabis plants and is a carboxylated primer molecule for cannabidiol (CBD). CBDa is converted to CBD by superheating, or by exposure to ultraviolet light or other oxidative stresses. The CBDa compound may also have its own effects, independent of its relationship to CBD.

At GVB, consumer engagement with CBDa appears to be rising exponentially. The 30-day sales period ending December 21, 2021 showed a 29% increase in CBDa order volume and a 214% increase in revenue; the next 30-day period, ending January 31, 2022, resulted in a 466.67% increase in order volume and a 672.73% increase in revenue. To meet the skyrocketing demand for CBDa products, GVB Biopharma plans to scale up its production and processing of CBDa products, and vastly increase its output.

As one of the most well-respected names in the hemp cannabinoid industry, GVB Biopharma’s commitment to advancing the highest quality consumer products remains second to none. With state-of-the-art facilities for hemp processing in Oregon, white-label consumer product manufacturing operations in Las Vegas, administrative headquarters in Los Angeles and national sales offices in Chicago, Denver and South Florida, GVB has demonstrated a capacity for massive—yet nimble and responsive—growth. Its vast national and global reach allows it to meet the exploding demand for hemp cannabinoids and be an indispensable industry partner for entrepreneurs and brands serving this market’s needs.

SOURCE GVB Biopharma

NEW YORK, Oct. 20, 2021 — GVB Biopharma, the leader in hemp-derived cannabinoid active ingredient production and white label product formulation, announced today that it has been named Leading Manufacturer of the Year at the 2021 New York City White Label Expo. The event, held annually in the fall, acts as a premier showcase and sourcing show for leading online retailers.

The award recognizes the outstanding manufacturer of white label products, which allow for rebranding by third parties. The White Label Expo describes three selection criteria for its Leading Manufacturer of the Year Award recipient: a trusting relationship with their clients, an industry-leading quality control system and a seamless customer experience. Three finalists were chosen, and GVB Biopharma was selected as the winner among more than 400 eligible companies. The award is one of four industry accolades given for outstanding performance in the areas of manufacturing, product innovation, service and private labeling.

“We’re working hard to push the industry forward with innovative products and heightened compliance standards,” said Phillip Swindells, Chief Executive Officer of GVB Biopharma. The company was recognized at the White Label Expo for its groundbreaking manufacturing and processing model, which has created a new industry standard for quality control and operational integrity.

The rigor of GVB Biopharma’s compliance measures and product quality standards has made it one of the most well-respected names in the hemp cannabinoid industry. Along with state-of-the-art facilities for hemp processing in Oregon, white-label consumer product manufacturing operations in Las Vegas, and national sales offices in Los Angeles, Chicago, Denver and South Florida, GVB has demonstrated a capacity for massive growth. Its vast national and global reach allows it to meet the exploding demand for hemp cannabinoids and be an indispensable industry partner for entrepreneurs and brands serving this market’s needs.

SOURCE GVB Biopharma

Handling certification from CCOF affirms GVB Biopharma’s position as the industry’s leading hemp processor. CCOF follows strict processes throughout its certification process, and in receiving CCOF certification, GVB Biopharma has clearly demonstrated its commitment to transparency and sustainability.

Organic certification of any kind is rare in the hemp industry. CCOF’s registry indicates that GVB Biopharma is one of a select few CBD producers to receive organic certification from this USDA-accredited certifier. In an industry that remains devoid of comprehensive regulation, CCOF certification demonstrates that GVB Biopharma is a uniquely trustworthy hemp-derived cannabinoid producer.

About GVB Biopharma

With primary domestic facilities in Las Vegas, Nevada and Central Oregon, GVB Biopharma is the nation’s leading hemp-derived cannabinoid producer. The GVB Biopharma team consists of more than 150 carefully selected employees including scientists, engineers, sales professionals, and marketing specialists.

Founded in 2016, GVB Biopharma has expanded its operations around the globe with international facilities in Europe and Latin America.

GVB Biopharma’s operations are separated into two primary arms: bulk extract production and white label product formulation. Customers can select from a wide array of bulk extracts to build their own products, or they can utilize GVB Biopharma’s pre-formulated white label product line.

As a recognized leader in cannabinoid extract engineering, GVB Biopharma offers bulk extracts ranging from CBN isolate to THC-free broad-spectrum distillate and everything in-between. GVB Biopharma is also a renowned producer of specialist extracts including crystal-resistant distillates and water-soluble cannabinoid liquids and powders.

Additionally, GVB Biopharma was one of the first hemp processors to offer bulk CBG in isolate and distillate form. Since then, GVB Biopharma has expanded to also offer a full line of CBN extracts.

GVB Biopharma cannabinoid extracts are tested multiple times during the production process to ensure potency and purity. Starting with genetically ideal seeds, GVB Biopharma uses rigorous SOPs to produce reliable and repeatable bulk ingredients suitable for use by even the most exacting customers.

GVB Biopharma can produce a full range of white label offerings including:

• Tinctures
• Pet products
• Oil-based topicals
• Water-based creams
• Water-based lotions
• Capsules
• Tablets
• Gummies
• Vapes
• & more

Customers have the option of choosing from among pre-formulated product types or requesting new types of formulations.

CCOF certification is only the latest in a long line of certifications GVB Biopharma has received. GVB Biopharma’s Oregon facility has been certified as food grade by the Oregon Department of Agriculture since inception, is NSF registered for cGMP dietary supplement manufacturing and has received ISO 9001:2015 certification. By actively pursuing all available certifications, GVB Biopharma distinguishes itself as an industry leader in compliance, transparency, and safety.

SOURCE GVB Biopharma

BOCA RATON, Fla., Oct. 13, 2020 — GVB Biopharma, a nutraceutical company specializing in hemp and cannabis-related consumer products, announced today that it has opened its fourth national sales and business development office in Boca Raton, FL. The Boca Raton office is GVB’s third new sales office opened this year, joining its sister offices in Los Angeles, Chicago and Denver.

Along with state-of-the-art facilities for hemp processing in Oregon, white-label consumer product manufacturing in Las Vegas, and administrative headquarters in Los Angeles, the domestic office expansion of GVB Biopharma has positioned the company for exponential growth in the coming years. The company’s sizable national reach matches the explosive consumer demand for hemp-derived cannabinoid products. By the end of 2020, the U.S. hemp market alone is expected to reach $4.7 billion in sales.

With offices on four continents, GVB Biopharma has also expanded its international footprint. Global GVB offices are located in Doncaster, U.K, Bogotá, Colombia and in Xiamen, China. These offices are part of a broad, disciplined strategy that has made GVB Biopharma one of the world’s fastest growing international hemp raw material and finished product manufacturers.

As demand for hemp cannabinoids rapidly grows, GVB’s services are embedded in the production processes for many of the market’s largest brands. Many leading consumer-facing cannabinoid companies rely on GVB’s raw material offerings and manufacturing capabilities. At the same time, GVB distinguishes itself in the hemp market with cutting-edge cannabinoid research and development, displaying its commitment to cannabinoid education for consumers and the public.

The rigor of GVB Biopharma’s compliance measures and product quality standards have made it one of the most well-respected names in the hemp cannabinoid industry. GVB has principled infrastructure for longevity and a visionary scope for expansion, positioning themselves as indispensable partners for entrepreneurs and brands aiming to meet this expanding market’s needs.

GVB Biopharma is actively seeking qualified personnel to join their rapidly expanding team. If you are interested in joining the new sales and business development office in Boca Raton, FL please send your resume to hr@gvbbiopharma.com.

LAS VEGAS, Aug. 6, 2020 — GVB Biopharma, a pharmaceutical company specializing in hemp and cannabis-related consumer products, announced today that it has established the process and infrastructure for producing medicinal products from cannabigerol (CBG).

With this venture, GVB Biopharma creates a scientific foundation and professional network for a research and development program for CBG, allowing for the rapid development of licensable intellectual property. In addition to CBG, this well-vetted process can be used to identify and develop other target molecules of interest.

The process will be established in two phases with two parts each. In the first phase, GVB will conduct extensive literature review of research on the endocannabinoid system and the effects of CBG, using the results to create an annotated database of scientific research. Next, GVB will oversee the chemical characterization of CBG, confirming the absence of pollutants and identifying important features like potency and shelf life.

In the second phase, GVB Biopharma will create a biological characterization of CBG and assess its therapeutic potential and other meaningful uses. These efforts allow GVB to compile scientific evidence showing the value of CBG products to regulatory agencies, allowing for efficient access to the marketplace.

GVB Biopharma sets the industry standard for rigor in developing, testing and manufacturing hemp and cannabinoid products for the discerning consumer. With its state-of-the-art facilities for hemp processing in Oregon and white-label consumer product manufacturing in Nevada, GVB Biopharma sets the standard for product quality. From using rigorous research, to testing the genetic stability of seeds, to verifying the cannabinoid capacity of its plants and purity of the distilled oil, the integrity of the GVB Biopharma process is reflected in every product.